The putative antipsychotic alstonine reverses social interaction withdrawal in mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 6, 2008, Pages 1449-1452

  de Moura Linck, Viviane ^a   Herrmann, Ana Paula ^a   Goerck, Greice Catrine ^a   Iwu, Maurice M ^b   Okunji, Christopher O ^b   Leal, Mirna Bainy ^a   Elisabetsky, Elaine ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSITY OF NIGERIA   (Nigeria)

Author keywords

Alstonine; Antipsychotics; MK801 induced social withdrawal; Negative symptoms; Social interaction

Indexed keywords

ALSTONINE; ANXIOLYTIC AGENT; CLOZAPINE; DIZOCILPINE; HALOPERIDOL; INDOLE ALKALOID; KETAMINE; NEUROLEPTIC AGENT; PHENCYCLIDINE; SULPIRIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; MENTAL DISEASE; MOUSE; NEGATIVE SYNDROME; NIGERIA; NONHUMAN; PSYCHOSOCIAL WITHDRAWAL; REINFORCEMENT; SOCIAL INTERACTION; SOCIAL LIFE;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; HALOPERIDOL; INTERPERSONAL RELATIONS; MALE; MICE; MOTOR ACTIVITY; SECOLOGANIN TRYPTAMINE ALKALOIDS; SOCIAL BEHAVIOR DISORDERS; SULPIRIDE;

EID: 47749115675     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.04.013     Document Type: Article

References (26)

1. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. International Journal of Neuropsychopharmacology, 7 Sup.1 (2004) S1-S5
2. Becker A., and Grecksch G. Ketamine-induced changes in rats behaviour: a possible animal model of schizophrenia. Test of predictive validity. Progress in Neuro-Psychopharmacology; 28 (2004) 1267-1277
3. Cepeda C., and Levine M.S. Where do you think you are going? The NMDA-D1 receptor trap. Science's STKE 333 (2006) pe20
4. Corbett R., Hartman H., Kerman L.L., Woods A.T., Strupczewski J.T., and Helsley G.C. Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacology Biochemistry and Behavior 45 1 (1993) 9-17
5. Costa-Campos L., Lara D.R., Nunes D.S., and Elisabetsky E. Antipsychotic-like profile of alstonine. Pharmacology Biochemistry and Behavior 60 1 (1998) 133-141
6. Costa-Campos L., Elisabetsky E., Lara D.R., Carlson T.J., King S.R., Ubillas R.M., et al. Antipsychotic profile of alstonine: ethnopharmacology of a traditional Nigerian botanical remedy. Anais da Academia Brasileira de Ciências 71 2 (1999) 189-201
7. Costa-Campos L., Dassoler S.C., Rigo A.P., Iwu M., and Elisabetsky E. Anxiolytic properties of the antipsychotic alkaloid alstonine. Pharmacology Biochemistry and Behavior 77 (2004) 481-489
8. Ellenbroek B.A., and Cools A.R. Animal models for the negative symptoms of schizophrenia. Behavioural Pharmacology 11 3-4 (2000) 223-233
9. Erhart S.M., Marder S.R., and Carpenter W.T. Treatment of schizophrenia negative symptoms: future prospects. Schizophrenia Bulletin 32 (2006) 234-237
10. File S.E. The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. Journal of Neuroscience Methods 2 (1980) 219-238
11. Huppert J.D., Weiss K.A., Lim R., Pratt S., and Smith T.E. Quality of life in schizophrenia: contributions of anxiety and depression. Schizophrenia Research 51 2-3 (2001) 171-180
12. Iwu M.M., and Court W.E. Root alkaloids of Rauwolfia comminsii Stapf. Planta Medica 32 2 (1977) 158-161
13. Iwu M.M., and Klayman D.L. Evaluation of the in vitro antimalarial activity of Picralima nitida extracts. Journal of Ethnopharmacology 36 2 (1992) 133-135
14. Kapur S., and Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5HT2 receptors implications for models of schizophrenia. Molecular Psychiatry 7 8 (2002) 837-844
15. Kristiasen L.V., Huerta I., Beneyto M., and Meador-Woodruff J.H. NMDA receptors and schizophrenia. Current Opinion in Pharmacology 7 (2007) 48-55
16. Nina I., and Kulkarni S.K. 5-HT2A receptor antagonists block MK-801-induced stereotypy and hyperlocomotion. European Journal of Pharmacology 358 (1998) 111-116
17. Powell C.M., and Miyakawa T. Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder?. Biological Psychiatry 59 (2006) 1198-1207
18. Quiao H., Noda Y., Kamei T., Nagai T., Furukawa H., Miura H., et al. Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. Neuropharmacology and Neurotoxicology, 12 (2001) 11-15
19. Rung J.P., Carlsson A., Markinhuhta K.R., and Carlsson M.L. (+)-MK801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 29 (2005) 827-832
20. Rung J.P., Carlsson A., Markinhuhta K.R., and Carlsson M.L. The dopaminergic stabilizers (-)-OSU6162 and ACR16 reverse (+)-MK801-induced social withdrawal in rats. Progress in Neuro-Psychopharmacology & Biological Psychiatry 29 (2005) 833-839
21. Sams Dodd F. Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behavioral Pharmacology 7 (1996) 3-23
22. Schultz S.H., North S.W., and Shields C.G. Schizophrenia: a review. American Family Physician 75 12 (2007) 1822-1829
23. Stahl S.M., and Buckley P.F. Negative symptoms of schizophrenia: a problem that will not go away. Acta Pychiatrica Scandinavica 115 (2007) 4-11
24. Stone J.M., Morrison P.D., and Pilowsky L.S. Glutamate and dopamine dysregulation in schizophrenia - a synthesis and selective review. Journal of Psychopharmacology 21 4 (2007) 440-452
25. Tamminga C.A., Buchanan R.W., and Gold J.M. The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. International Journal of Psychopharmacology 13 supl.3 (1998) 21-S26
26. 2A and muscarinic receptors. Psychopharmacology 141 (1999) 267-278